MTOR and neoplasm: Finally, a combination of an AURKA inhibitor, MLN8237 (alisertib) with NVP-BEZ235 in a 786-0 VHL-null mouse xenograft model of RCC dramatically reduced tumor burden, highlighting the potential for co-inhibition of AKT, mTOR and AURKA as a clinical intervention strategy.